@AnotherBio A dissolution or liquidation or $ARTV here would be such a responsible and welcome announcement for shareholders....
Certainly one of the possible outcomes of the strategic review....
Based on what you've described - low prorate, expensive borrow, with 29% of MMED float short, wouldn't you want to short the spread (Long MMED / short MDT)? Sitting at 4.55x ratio, Max ratio is 4.59x, ain't going above that, which is your risk. Sets-up for a Pentwater type fund to buy MMED and pull borrow akin to $CAR...
@puppyeh1@kingdomcapadv re: $DOMO
For $LOGC/$WISH, '24 was a different time. In '25, $LOGC was at 7%. Today Shells tighter, some (i.e. biotech shells) at premiums. ii. Existing holders thought $ buyout, not shell, exiting. iii. J.James may deserve discount. Whether <> 24% discount (31% return) is the ?
$MAPS
Doug Francis and this Board betting no one will challenge them because the money and time commitment not worth it.
But, the upside here is material. With a non-staggered Board provision, it's an excellent set-up for an Activist that can navigate OTC dynamics, to slowly accumulate a $12m+ position and nominate a proxy slate for next year.
@moazzam0_reddit@RodAlzmann
@A_May_MD 2 KS cases in 4,630 patients
And these two could have been identified with a pre-treatment simple blood test for HHV-8
....and a large market where they already have the dominant drug
Not perfect, but why wouldn't it work out for them?
@AaronRosenblum5@clinmean@richtrades100 Same Cowen analyst's 2/2/26 note where he gives them no value for rev 2031 onwards and uses a 16% discount rate and ***STILL*** comes out at $5.30/sh for $TBPH's Yupelri stake.
@whiteoutcapital Three questions:
(i) Who are these cutting edge tech companies?
(ii) Are these customers stable / making money?
(iii) If valued on Rev multiple, what's a reasonable Rev #?
Let's discuss further via DM.
@Stmkrs $IMA is a reasonable thesis.
IMG-007 piggy-backing on an established MOA.
If half-life++, receptor target increases efficacy is the key issue and is TBD...
Company will be active in the investor circuit in '26...
Tax loss selling has it oversold at these levels...